Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II open-label multicenter study of SHR-8068 combined with adebrelimab and platinum-based chemotherapy in advanced non-small cell lung cancer
CTR20221333Phase 2Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CS1002 in non-small cell lung cancer (NSCLC), sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Aug 2022; status: active.
02
Drugs
CS1002
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20221333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221333.